Certified by Founder
Lodge
OncoPep, Inc.
start up
United States
- Boston, Massachusetts
- 09/12/2021
- Series D
- $11,000,000
Through targeting multiple tumor-associated antigens with an investigational multi-peptide vaccine and a multi-tumor antigen adoptive (MTAA) T cell therapy, OncoPep’s T cell focused technologies are designed to be used on their own or in combination with other immunotherapeutics.
- Industry Biotechnology Research
- Website https://oncopep.com/
- LinkedIn https://www.linkedin.com/company/oncopep-inc./
Corgi | $108,000,000 | (Jan 9, 2026)
Corsera Health | $80,000,000 | (Jan 9, 2026)
Oasys | $4,600,000 | (Jan 9, 2026)
Vizgen | $48,000,000 | (Jan 9, 2026)
Poplar Therapeutics | $50,000,000 | (Jan 9, 2026)
Carna Health | $8,000,000 | (Jan 9, 2026)
Alveus Therapeutics Inc | $160,000,000 | (Jan 9, 2026)
AgileRL | $7,500,000 | (Jan 9, 2026)
Soley Therapeutics | $200,000,000 | (Jan 9, 2026)
EpiBiologics | $107,000,000 | (Jan 9, 2026)
SpangleAI | $15,000,000 | (Jan 9, 2026)
Presto Phoenix, Inc. | $10,000,000 | (Jan 9, 2026)